Vesugen Guía & Tabla de Dosis

What is Vesugen?

Vesugen is a short, synthetic peptide made up of just three amino acids — lysine, glutamic acid, and aspartic acid (Lys-Glu-Asp). That tiny chain puts it in a special class of compounds called peptide bioregulators. Think of bioregulators as tiny molecular keys designed to fit very specific locks inside the body. Vesugen's lock appears to be in the vascular system — the network of blood vessels that carries oxygen and nutrients everywhere you need them.

This is a research-use-only compound. It is not approved as a medicine and is not intended for human self-administration. Everything on this page is for educational and scientific reference only.

How Vesugen Works

Here's a simple way to picture it: imagine your blood vessel walls are made of bricks (cells) held together by mortar. Over time, as the body ages, the bricklaying slows down — fewer new cells are made to replace worn-out ones. Vesugen appears to act like a foreman on that construction site, nudging the workers back into action.

Scientists believe the peptide works at an epigenetic level — meaning it influences which genes get switched on, without actually changing the DNA code itself. Specifically, laboratory studies found that Vesugen interacts with the promoter region of the MKI67 gene, which controls a protein called Ki-67. Ki-67 is a well-known marker of cell proliferation (a sign that cells are actively dividing). In aging vascular endothelial cells — the thin layer of cells lining every blood vessel — Ki-67 levels tend to fall. Vesugen appeared to help restore that activity in cell cultures taken from both young and old animals.^[2]

In a separate line of research, Vesugen was shown to stimulate the expression of CXCL12 and WEGC1, proteins that guide how cells differentiate (specialize into their final job). This effect was most noticeable in aging cell cultures, hinting that the peptide may be particularly relevant when cells have already started to slow down.^[4]

What the Research Shows

All published research on Vesugen is preliminary — mostly cell studies, animal models, and small human observational studies. Here is a plain-language summary:

• Cell proliferation in blood vessels: In lab cultures, Vesugen stimulated the Ki-67 proliferation protein in aging vascular endothelial cells. The peptide appeared to dock directly onto the promoter region of the Ki-67 gene, suggesting a gene-regulatory (epigenetic) mechanism behind its vascular effects.^[2]
• Cell differentiation: In aging human fibroblast cultures (connective tissue cells), Vesugen specifically increased expression of differentiation markers — an effect that was stronger in older cell cultures than in younger ones, which the researchers flagged as a possible geroprotective (aging-slowing) mechanism.^[4]
• Antihypoxic properties: In a hypoxia (low-oxygen) model, Vesugen — along with several related short peptides — demonstrated antihypoxic properties, meaning it appeared to help cells cope better under oxygen-deficient conditions.^[5]
• Cell membrane stability: Lab tests found that Vesugen and related short peptides increased the stability of red blood cell membranes against osmotic stress (the kind of force that can rupture cell walls). The peptides also appeared to participate in regulating the balance between cell death (apoptosis) and cell survival.^[6]
• Small human study: In a study of 32 people aged 41–83 with polymorbidity (multiple chronic conditions) and vascular or traumatic brain syndrome, Vesugen demonstrated a significant anabolic effect and was associated with improvements in biological age indicators. Notably, Vesugen showed a more pronounced geroprotective effect than a companion peptide (Pinealon) in this group. The researchers also noted that Vesugen did not affect chromatin condensation, suggesting it is safe at the nuclear genetic level — though they called for further study on this point.^[1]
• Pineal immune cells: In pineal gland organotypic cultures, Vesugen did not change immune cell differentiation but did enhance the proliferation potential of those immune cells.^[3]

What Vesugen Is Being Studied For

Based on the published literature, researchers are primarily interested in Vesugen in the following contexts:

• Vascular aging and endothelial cell health
• Geroprotection — slowing biological markers of aging
• Cell proliferation and differentiation in aging tissues
• Resistance to hypoxic (low-oxygen) stress
• Neurological conditions with a vascular component (e.g., organic brain syndrome)

Again, none of these applications are approved medical uses. This compound is being studied in research settings only.

How Vesugen Is Dosed in Research

Because published human dosing data for Vesugen is very limited, dosing in research settings varies. The small clinical study referenced above used standardized peptide preparations, but exact protocols differ between research groups. The dosage chart on this page summarizes the available reference ranges used in published studies, and the calculator on this page can help researchers work out quantities based on concentration and volume. Always consult the dosage chart before preparing any research solution, and note that no standard human dose has been established or approved.

Mixing and Storing Vesugen

Vesugen is typically supplied as a lyophilized (freeze-dried) powder. To reconstitute it, researchers generally add bacteriostatic water or sterile saline slowly along the inside wall of the vial — not directly onto the powder — and swirl gently rather than shaking, which can damage the peptide chain. Once mixed, the solution should be stored in a refrigerator (around 2–8 °C / 36–46 °F) and kept away from light. Unused powder (before reconstitution) is best kept frozen. Always label your vials with the date of reconstitution and discard after the recommended window — typically within 2–4 weeks once reconstituted, depending on storage conditions. This compound is for laboratory and research use only; all handling should follow appropriate research protocols.

Sources

1. [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]. — Advances in gerontology = Uspekhi gerontologii, 2015. PMID 26390612.
2. [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging]. — Advances in gerontology = Uspekhi gerontologii, 2014. PMID 25051766.
3. Peptidegic stimulation of differentiation of pineal immune cells. — Bulletin of experimental biology and medicine, 2011. PMID 22803057.
4. Peptides tissue-specifically stimulate cell differentiation during their aging. — Bulletin of experimental biology and medicine, 2012. PMID 22808515.
5. [Investigation of antihypoxic properties of short peptides]. — Advances in gerontology = Uspekhi gerontologii, 2008. PMID 18546825.
6. [Biological activity of regulatory peptides in model experiments in vitro]. — Advances in gerontology = Uspekhi gerontologii, 2008. PMID 18546826.